Thomas A. Fitzgerald
Board Member
Transcode Therapeutics, Inc. (RNAZ)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-01-13–present
-
Current
2018-01-01–present
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Transcode Therapeutics, Inc. (RNAZ) | Vice President, Chief Financial Officer, and former interim Chief Executive Officer | $480,000 | $1,069,615 |
| 2024 | Transcode Therapeutics, Inc. (RNAZ) | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $255,076 | $956,966 |
| 2023 | Transcode Therapeutics, Inc. (RNAZ) | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $358,138 | $426,862 |
| 2022 | Transcode Therapeutics, Inc. (RNAZ) | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $371,000 | $560,701 |
| 2021 | Transcode Therapeutics, Inc. (RNAZ) | Vice President and Chief Financial Officer | $180,000 | $317,613 |
| 2020 | Transcode Therapeutics, Inc. (RNAZ) | Vice President and Chief Financial Officer | — | $15,386 |
Recent activity
No earnings-call appearances or filed executive changes recorded yet.